Literature DB >> 30830521

Immunotherapy: Current Status and Future Perspectives.

Charalampos S Floudas1, Gagandeep Brar2, Tim F Greten2,3.   

Abstract

Hepatocellular carcinoma (HCC) has an increasing incidence and dismal prognosis, with few systemic treatments approved, including several small molecule tyrosine kinase inhibitors. The application of immune checkpoint inhibitors (ICIs) to HCC has resulted in durable activity, and further evaluation is ongoing. In this review, we discuss the immunologic principles and the mechanism of action of the ICIs and present the relevant clinical data. Furthermore, we provide an overview of the current and emerging immunotherapeutic approaches for HCC, such as combination treatments, vaccines, and cellular therapies.

Entities:  

Keywords:  Adoptive cellular immunotherapy; B7-H1 antigen; CTLA-4 antigen; Hepatocellular carcinoma; Immunotherapy; Programmed cell death 1 receptor

Mesh：

Substances：

Year:  2019        PMID： 30830521     DOI： 10.1007/s10620-019-05516-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.487


  73 in total

1.  Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.

Authors:  Hidetoshi Nakagawa; Eishiro Mizukoshi; Eiji Kobayashi; Toshikatsu Tamai; Hiroshi Hamana; Tatsuhiko Ozawa; Hiroyuki Kishi; Masaaki Kitahara; Tatsuya Yamashita; Kuniaki Arai; Takeshi Terashima; Noriho Iida; Kazumi Fushimi; Atsushi Muraguchi; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2017-02-07       Impact factor: 22.682

Review 2.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

6.  Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy.

Authors:  I Haruta; K Yamauchi; A Aruga; T Komatsu; K Takasaki; N Hayashi; F Hanyu
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-05

7.  T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

Authors:  Lisa H Butterfield; Antoni Ribas; Wilson S Meng; Vivian B Dissette; Saral Amarnani; Huong T Vu; Elisabeth Seja; Karen Todd; John A Glaspy; William H McBride; James S Economou
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.

Authors:  Yu Sawada; Toshiaki Yoshikawa; Kazuya Ofuji; Mayuko Yoshimura; Nobuhiro Tsuchiya; Mari Takahashi; Daisuke Nobuoka; Naoto Gotohda; Shinichiro Takahashi; Yuichiro Kato; Masaru Konishi; Taira Kinoshita; Masafumi Ikeda; Kohei Nakachi; Naoya Yamazaki; Shoichi Mizuno; Tadatoshi Takayama; Kenji Yamao; Katsuhiko Uesaka; Junji Furuse; Itaru Endo; Tetsuya Nakatsura
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

10.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

Authors:  Jeffrey J Wallin; Johanna C Bendell; Roel Funke; Mario Sznol; Konstanty Korski; Suzanne Jones; Genevive Hernandez; James Mier; Xian He; F Stephen Hodi; Mitchell Denker; Vincent Leveque; Marta Cañamero; Galina Babitski; Hartmut Koeppen; James Ziai; Neeraj Sharma; Fabien Gaire; Daniel S Chen; Daniel Waterkamp; Priti S Hegde; David F McDermott
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919
View more
  10 in total

Review 1.  Potential human immunotherapeutics for plague.

Authors:  Voahangy Andrianaivoarimanana; Lovasoa Nomena Randriantseheno; Kristoffer M Moore; Nicola J Walker; Steven G Lonsdale; Sarah Kempster; Neil A Almond; Minoarisoa Rajerison; E Diane Williamson
Journal:  Immunother Adv       Date:  2021-10-05

2.  Experimental Study of Potential CD8+ Trivalent Synthetic Peptides for Liver Cancer Vaccine Development Using Sprague Dawley Rat Models.

Authors:  Sidra Zafar; Baogang Bai; Jinlei Guo; Syed Aun Muhammad; Syeda Tahira Qousain Naqvi; Muhammad Nauman Shabbir; Imran Imran; Rehan Sadiq Shaikh; Amjad Ali
Journal:  Biomed Res Int       Date:  2022-05-31       Impact factor: 3.246

3.  A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer.

Authors:  Amedeo Amedei; Fatemeh Asadzadeh; Francesco Papi; Maria Giuliana Vannucchi; Veronica Ferrucci; Iris A Bermejo; Marco Fragai; Carolina Vieira De Almeida; Linda Cerofolini; Stefano Giuntini; Mauro Bombaci; Elisa Pesce; Elena Niccolai; Francesca Natali; Eleonora Guarini; Frank Gabel; Chiara Traini; Stefano Catarinicchia; Federica Ricci; Lorenzo Orzalesi; Francesco Berti; Francisco Corzana; Massimo Zollo; Renata Grifantini; Cristina Nativi
Journal:  iScience       Date:  2020-06-06

4.  An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma.

Authors:  Xiaodong Wang; Yuquan Wu; Dongyue Wen; Lin-Yong Wu; Yujia Zhao; Yun He; Hong Yang
Journal:  Med Sci Monit       Date:  2020-05-31

5.  Application Of Adoptive Immunotherapy In Ovarian Cancer.

Authors:  Siyu Yang; Xiaojiao Yin; Ying Yue; Siqing Wang
Journal:  Onco Targets Ther       Date:  2019-09-27       Impact factor: 4.147

Review 6.  Employing Parasite Against Cancer: A Lesson From the Canine Tapeworm Echinococcus Granulocus.

Authors:  Wang Guan; Xiaoqin Zhang; Xiao Wang; Shun Lu; Jun Yin; Jinxin Zhang
Journal:  Front Pharmacol       Date:  2019-09-25       Impact factor: 5.810

7.  Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers.

Authors:  Jin-Min Xue; Yi Liu; Ling-Hong Wan; Yu-Xi Zhu
Journal:  Med Sci Monit       Date:  2020-02-08

8.  A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  Front Mol Biosci       Date:  2020-11-13

Review 9.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

Review 10.  Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.